<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02179775</url>
  </required_header>
  <id_info>
    <org_study_id>90-01-64-3456</org_study_id>
    <nct_id>NCT02179775</nct_id>
  </id_info>
  <brief_title>Effect of &quot;Sekanjabin e Safarjali&quot; (Quince Oxymel) in the Prevention of Migraine Attacks</brief_title>
  <official_title>Comparison of Effectiveness of &quot;Sekanjabin e Safarjali&quot; (Quince Oxymel), Propranolol and Placebo in the Prevention of Migraine Attacks in Patients With Simultaneous Upper Gastrointestinal Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shiraz University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shiraz University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Quince Oxymel is effective in the
      prevention of Migraine attacks in patients with simultaneous upper gastrointestinal
      dysfunction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, placebo-controlled, triple blinded clinical study to evaluate the
      effects of oral use of &quot;Sekanjebin e Safarjali&quot; (Quince Oxymel) in the Prevention of Migraine
      attacks in patients with simultaneous upper gastrointestinal dysfunction.45 patients with
      Migraine headache aged between 15-70, after taking signed informed consent, according to the
      International headache society criteria for headache [2] are included in this trial. 45 cases
      with Migraine headache with simultaneous upper gastrointestinal dysfunction will allocate to
      three arms by using simple randomization. Quince Oxymel, propranolol and placebo will be
      given as encoded, innominate bottles with the same shape and color. Quince oxymel and placebo
      will be prescribed as 10 cc, three times a day for 4 weeks. Frequency, duration and intensity
      of Migraine Attacks at the beginning time and during 4 weeks of trial, will be evaluated, as
      the primary outcome measures.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2014</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>frequency of headache attacks</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>duration of headache attacks</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain Scores as assessed by the Visual Analog Scale</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>self-reported improvement of upper gastrointestinal symptoms (by percent)</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Migraine Headache</condition>
  <condition>Gastric Diseases</condition>
  <arm_group>
    <arm_group_label>propranolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Quince's oxymel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>propranolol</intervention_name>
    <arm_group_label>propranolol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quince's oxymel</intervention_name>
    <arm_group_label>Quince's oxymel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  minimum age of 18 years old

          -  giving a written informed consent

          -  having at least 2 migraine attacks per month

        Exclusion Criteria:

          -  patients older than 70 years old

          -  patients with Diabetes mellitus

          -  patients with chronic obstructive pulmonary disease and asthma

          -  pregnancy

          -  severe depression

          -  patients affected by sexual disorders

          -  bradyarrhythmic patients

          -  positive history of hypersensitivity reactions to quince, ginger, propranolol or
             naproxen
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abdolhamid Shariat, MD, Assistant Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shiraz University of Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shiraz University of Medical Sciences</name>
      <address>
        <city>Shiraz</city>
        <state>Fars</state>
        <zip>+98711</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shariat, MD</last_name>
      <email>shariat123@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Abdolhamid Shariat, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shiraz University of Medical Sciences</name>
      <address>
        <city>Shiraz</city>
        <state>Fars</state>
        <zip>+98711</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hashempur, MD, PhD</last_name>
      <email>hashempur@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Mohammad H Hashempur, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 27, 2014</study_first_submitted>
  <study_first_submitted_qc>June 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2014</study_first_posted>
  <last_update_submitted>July 9, 2014</last_update_submitted>
  <last_update_submitted_qc>July 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shiraz University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Mohammad Hashem Hashempur</investigator_full_name>
    <investigator_title>MD, PhD of Iranian traditional medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
    <mesh_term>Headache</mesh_term>
    <mesh_term>Stomach Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propranolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

